Skip to contentpdufa.bio

ARV-393 (zaloblideg, PROTAC BCL6 degrader)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ARV-393 (zaloblideg, PROTAC BCL6 degrader) is an Arvinas, Inc. program in diffuse large B-cell lymphoma (DLBCL). Its next catalyst is a Readout on Dec 14, 2026.

ARVN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: diffuse large B-cell lymphoma (DLBCL); relapsed/refractory non-Hodgkin lymphoma. Sponsor: Arvinas, Inc. (ARVN). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 14, 2026ARVNReadout · Q4 2027ARVN

Questions

When is ARV-393 (zaloblideg, PROTAC BCL6 degrader)'s next FDA decision or readout?

The next tracked catalyst for ARV-393 (zaloblideg, PROTAC BCL6 degrader) is a Readout on Dec 14, 2026.

What happened at ARV-393 (zaloblideg, PROTAC BCL6 degrader)'s most recent FDA decision?

No FDA decision for ARV-393 (zaloblideg, PROTAC BCL6 degrader) is in our archive yet.

What is ARV-393 (zaloblideg, PROTAC BCL6 degrader) used for?

In our records ARV-393 (zaloblideg, PROTAC BCL6 degrader) is under review or in development for diffuse large B-cell lymphoma (DLBCL); relapsed/refractory non-Hodgkin lymphoma.

Who makes ARV-393 (zaloblideg, PROTAC BCL6 degrader)?

Arvinas, Inc. (ARVN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.